Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Breast cancer facts & figures, Am Cancer Soc, 2021, Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed August 4, 2021.
- Breast cancer epidemiology and risk factors.Clin Obstet Gynecol. 2016; 59: 651-672
- Genetics of breast cancer: a topic in evolution.Ann Oncol. 2015; 26: 1291-1299
- The role of genetic testing in patients with breast cancer: a review.JAMA Surg. 2017; 152: 589-594
- Non-BRCA familial breast cancer: review of reported pathology and molecular findings.Pathology. 2017; 49: 363-370
- Beyond BRCA: new hereditary breast cancer susceptibility genes.Cancer Treat Rev. 2015; 41: 1-8
- Consensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer.(Available at:) (Accessed August/13/2018)
- Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer.JAMA. 2019; 322: 652
- USPSTF recommendations for BRCA1 and BRCA2 testing in the context of a transformative national cancer control plan.JAMA Netw Open. 2019; 2: e1910142
- Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2021; 19: 77-102
- A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center.Clin Genet. 2000; 58: 299-308
- Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.Breast Cancer Res Treat. 2017; 164: 263-284
- Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.J Natl Cancer Inst. 1989; 81: 1879-1886
- Projecting individualized absolute invasive breast cancer risk in asian and pacific islander american women.J Natl Cancer Inst. 2011; 103: 951-961
- Projecting individualized absolute invasive breast cancer risk in african american women.J Natl Cancer Inst. 2007; 99: 1782-1792
- Projecting Individualized absolute invasive breast cancer risk in US hispanic women.J Natl Cancer Inst. 2017; 109: djw215
- Diagnostic accuracy of the Gail model in the Black Women's Health Study.Breast J. 2007; 13: 332-336
- Assessment of the accuracy of the Gail model in women with atypical hyperplasia.J Clin Oncol. 2008; 26: 5374-5379
- Genetic analysis of breast cancer in the cancer and steroid hormone study.Am J Hum Genet. 1991; 48: 232-242
- Breast cancer risk-assessment models.Breast Cancer Res. 2007; 9: 213
- Assessing risk of breast cancer: a review of risk prediction models.J Breast Imaging. 2021; 3: 144-155
- Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction.Cancer. 1994; 73: 643-651
- Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.Am J Hum Genet. 1998; 62: 145-158
- Recent enhancements to the genetic risk prediction model BRCAPRO.Cancer Inform. 2015; 14s2: CIN.S17292
- A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.Br J Cancer. 2002; 86: 76-83
- The BOADICEA model of genetic susceptibility to breast and ovarian cancer.Br J Cancer. 2004; 91: 1580-1590
- The tyrer–cuzick model inaccurately predicts invasive breast cancer risk in women with LCIS.Ann Surg Oncol. 2020; 27: 736-740
- Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.J Clin Oncol. 2010; 28: 3591-3596
- Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.Genet Med. 2015; 17: 630-638
Cosgrove J., Genetic services: information on genetic counselor and medical geneticist workforces, In: Office G.A., Online, 2019, United State Government Accountability Office, 1-45, Available at: https://www.gao.gov/assets/gao-20-593.pdf. Accessed January 4, 2022..
- Germline genetic testing: what the breast surgeon needs to know.Ann Surg Oncol. 2019; 26: 2184-2190
- Linkage of early-onset familial breast cancer to chromosome 17q21.Science. 1990; 250: 1684-1689
- Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.Science. 1994; 265: 2088-2090
Supreme Court Decision in Association for Molecular Pathology v. Myriad Genetics, Inc. 2013. Available at: https://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf. Accessed September 11, 2016.
- What's new in genetic testing for cancer susceptibility?.Oncology (Williston Park). 2016; 30: 787-799
- Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes.Ann Surg Oncol. 2017; 24: 3067-3072
- Disparities in genetic testing for heritable solid-tumor malignancies.Surg Oncol Clin N Am. 2022; 31: 109-126
- Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.Breast Cancer Res Treat. 2019; 178: 151-159
- Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center.J Gen Intern Med. 2021; 36: 35-42
- Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.Breast J. 2009; 15: S56-S62
- Disparities in genetic testing and care among black women with hereditary breast cancer.Curr Breast Cancer Rep. 2020; 12: 125-131
- Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.Cancer. 2017; 123: 2497-2505
- Genetic counseling and testing in african american patients with breast cancer: a nationwide survey of US breast oncologists.J Clin Oncol. 2021; 39: 4020-4028
- The value of a genetic counselor for patient identification.J Clin Oncol. 2012; 30: 97
- Impact of an embedded genetic counselor on breast cancer treatment.Breast Cancer Res Treat. 2018; 169: 43-46
Daly M.B., Pal T., Arun B., et al., NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2022. Available online at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed January 4, 2022.
- The breast comprehensive management of benign and malignant diseases.5th ed. Elsevier, Philadelphia, PA2018
- Breast density implications and supplemental screening.Eur Radiol. 2019; 29: 1762-1777
- The role of ultrasound in breast cancer screening: the case for and against ultrasound.Semin Ultrasound CT MR. 2018; 39: 25-34
- Performance of dual-energy contrast-enhanced digital mammography for screening women at increased risk of breast cancer.Radiology. 2019; 293: 81-88
- A systematic review of elastography, electrical impedance scanning, and digital infrared thermography for breast cancer screening and diagnosis.Breast Cancer Res Treat. 2013; 137: 665-676
- Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature.Ann Surg Oncol. 2015; 22: 370-376
- Risk-reducing mastectomy for the prevention of primary breast cancer.Cochrane Database Syst Rev. 2018; 4: Cd002748
- Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.Breast Cancer Res Treat. 2019; 177: 723-733
- Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery.Breast. 2010; 19: 462-469
- Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.Cochrane Database Syst Rev. 2019; 10: Cd012894
- Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.PLoS One. 2015; 10: e0120189
- Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients.Ann Surg. 2019; 270: 364-372
- Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers.J Clin Oncol. 2016; 34: 409-418
- Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.Am J Surg. 2016; 212: 660-669
- Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.N Engl J Med. 2017; 377: 523-533
- Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.N Engl J Med. 2017; 377: 523-533
- Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.N Engl J Med. 2018; 379: 753-763
- NCCN Guidelines: Breast Cancer (version 1.2022) 2021;1.(Available at:) (Accessed December 13, 2021)
- BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.J Clin Oncol. 2002; 20: 2701-2712
- The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.Br J Cancer. 2008; 98: 1457-1466
- https://ccge.medschl.cam.ac.uk/boadicea/boadicea-web-application/Date accessed: January 4, 2022
- https://ems-trials.org/riskevaluator/Date accessed: January 4, 2022
Article info
Publication history
Published online: October 17, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
